急性肺损伤/急性呼吸窘迫综合征的药物治疗

Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome

急性肺损伤(acute lung injury,ALI)/急性呼吸窘迫综合征(acute respiratory dysfunction syndrome,ARDS)是危重病医学的重要课题,死亡率很高。尽管一些药物治疗包括肺表面活性物质、一氧化氮、糖皮质激素以及利索茶碱已经在ALI/ARDS患者中应用,但是没有一种药物可降低死亡率。本文综述了ALI/ARDS治疗药物的临床试验结果及其目前推荐应用的等级,同时也就一些有望在未来临床应用的药物,如β2-受体激动剂、角质化细胞生长因子以及活化蛋白-C进行讨论。

Acute lung injury and the acute respiratory distress syndrome are important thesis of the critical care medicine with a high mortality.Though the several pharmacological therapies including surfactant,nitric oxide,glucocorticoids and lysofylline have been studied in the patients with acute lung injury and acute respiratory distress syndrome,none of these pharmacological treatments can reduce mor-tality.This article provides an overview of pharmacological therapies of acute lung injury and the acute respiratory distress syndrome tested in clinical trials and current recommendations for their use as well as a discussion of potential pharmacological therapies in future including β2-adrenergic agonist therapy,keratinocyte growth factor and activated protein C.